低分子肝素在治疗新生儿败血症的疗效评估

Evaluation of Effect of Low Molecular Weight Heparin in Treatment of Neonatal Septicemia

目的探讨低分子肝素治疗新生儿败血症的临床疗效及安全性。方法选取本院收治的20例新生儿败血症的患儿,均在常规基础上给予低分子肝素治疗,观察其疗效、炎性及肝肾功能指标变化情况,统计并发症发生率。结果 20例患儿的治疗总有效率为80%,治疗后患儿白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)水平均较治疗前显著下降(P <0.05),谷丙转氨酶(ALT)、血肌酐(Cr)治疗前后差异无统计学意义(P> 0.05)。治疗过程中无严重并发症,未见患儿死亡。结论低分子肝素治疗新生儿败血症能提高疗效,有效控制感染,对患儿肝肾功能无明显影响,安全性较高。

Objective To investigate the efficacy and safety of low molecular weight heparin(LMWH)in the treatment of neonatal septicemia.Methods Twenty cases of neonatal septicemia in our hospital were treated with low molecular weight heparin(LMWH)on the basis of routine treatment.The curative effect,the changes of inflammatory and hepatic and renal function indexes and the incidence of complications were observed.Results The total effective rate of 20 cases was 80%.After treatment,the level of(WBC),C reactive protein(CRP),procalcitonin(PCT)in leukocyte count was significantly lower than that before treatment(P<0.05),and the level of(ALT),was significantly lower than that before treatment(P<0.05).Difference of serum creatinine(Cr)before and after treatment There was no significant difference(P>0.05).There were no serious complications and no death.Conclusion Low molecular weight heparin treatment of neonatal septicemia can improve the curative effect,control infection effectively,have no obvious influence on the liver and kidney function of children,and have high safety.